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operative outcomes in patients undergoing adult cervical deformity (ACD) surgery. SUMMARY OF
BACKGROUND DATA BMP has been shown to stimulate bone growth and improve fusion rates in
spine surgery. However, the impact of BMP on reoperation rates and postoperative complication rate
is controversial. METHODS We queried the MarketScan database to identify patients who underwent
ACD surgery from 2007-2015. Patients were stratified by BMP use in the index operation. Patients
under 18 and those with any history of tumor or trauma were excluded. Baseline demographics and
comorbidities, postoperative complication rates and reoperation rates were analyzed. RESULTS A total
of 13,549 patients underwent primary ACD surgery, of which 1155 (8.5%) had intraoperative BMP use.
The overall 90-day complication rate was 27.6% in the non-BMP cohort and 31.1% in the BMP cohort
(p < 0.05). Patients in the BMP cohort had longer average length of stay (4.0 days vs 3.7 days, p <
0.05) but lower revision surgery rates at 90-days (14.5% vs 28.3%, p < 0.05), 6 months (14.9% vs 28.6%,
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Abstract 
Study Design: An epidemiological study using national administrative data from the 
MarketScan database. 
Objective: To identify the impact of bone morphogenetic protein (BMP) on postoperative 
outcomes in patients undergoing adult cervical deformity (ACD) surgery. 
Summary of Background Data: BMP has been shown to stimulate bone growth and 
improve fusion rates in spine surgery. However, the impact of BMP on reoperation rates and 
postoperative complication rate is controversial.  
Methods: We queried the MarketScan database to identify patients who underwent ACD 
surgery from 2007-2015. Patients were stratified by BMP use in the index operation. Patients 
under 18 and those with any history of tumor or trauma were excluded. Baseline 
demographics and comorbidities, postoperative complication rates and reoperation rates were 
analyzed. 
Results: A total of 13,549 patients underwent primary ACD surgery, of which 1155 (8.5%) 
had intraoperative BMP use. The overall 90-day complication rate was 27.6% in the non-
BMP cohort and 31.1% in the BMP cohort (p < 0.05).  Patients in the BMP cohort had longer 
average length of stay (4.0 days vs 3.7 days, p < 0.05) but lower revision surgery rates at 90-
days (14.5% vs 28.3%, p < 0.05), 6 months (14.9% vs 28.6%, p < 0.05), 1 year (15.7% vs 
29.2%, p < 0.05), and 2 years (16.5% vs 29.9%, p < 0.05) postoperatively. BMP use was 
associated with higher payments throughout the 2-year follow-up period ($107,975 vs 
$97,620, p < 0.05). When controlling for baseline group differences, BMP use independently 
increased the odds of postoperative complication (OR 1.22, 95% CI 1.1 – 1.4) and reduced 
the odds of reoperation throughout 2-years of follow-up (OR 0.49, 95% CI 0.4 – 0.6). 
Conclusions: Intraoperative BMP use has benefits for fusion integrity in ACD surgery but is 
associated with increased postoperative complication rate. Spine surgeons should weigh these 
benefits and drawbacks to identify optimal candidates for BMP use in ACD surgery. 
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Key Points 
 Patients with BMP use for ACD surgery have longer length of stay, but lower rates of 
revision surgery 
 BMP use was associated with higher payments throughout the 2-year follow-up 
period 
 Though BMP use was associated with increased odds for developing a postoperative 
complication, it reduced the odds for reoperation at all time points throughout 2-years 
of follow-up  
 Intraoperative BMP use increases fusion integrity, but these benefits must be weighed 




Cervical spinal deformity can have a significant impact on patient health related 
quality of life (HRQOL).1 Though many recent publications have described the impact of 
corrective surgery on patients with deformities of the thoracolumbar spine, the literature 
surrounding cervical re-alignment is sparse.2 High postoperative complication rates, implant 
failure, and need for revision remain significant concerns after these operations, with age, 
number of levels within the fusion construct, and baseline comorbidities having been 
identified as important predictors of increased postoperative morbidity.3-6 As such, quality 
improvement efforts must focus on identifying clinical strategies that may improve both 
short- and long-term surgical outcomes. 
Bone morphogenetic protein 2 (BMP-2) was first identified by Marshall Urist in 1965 
as a potent osteo-inductive agent.7 Food and Drug Administration (FDA) approval of rhBMP-
2 in 2002 for single-level anterior lumbar interbody fusion (ALIF) led to an increase in its on- 
and off-label use for various spinal fusion procedures.8-13 Indeed, following studies 
demonstrated that BMP may reduce operative time and length of stay in patients undergoing 
spine surgery.10,14-18 However, there have been studies suggesting an increased risk of 
postoperative complications with the use of BMP.19-22 
BMP use in spinal deformity surgery remains controversial, with studies indicating 
that rates of reoperation are similar with and without BMP.23,24 However, a 2015 study 
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utilizing a statewide administrative dataset found a 7.5-fold decrease in reoperations due to 
pseudoarthrosis with the use of BMP intraoperatively.25 The debate regarding the risks and 
benefits of BMP are ongoing and the practice of individual surgeons differs considerably 
with regards to its utilization. Thus, we aimed to utilize a national claims dataset and provide 
insight into the impact of intraoperative BMP on postoperative complications, reoperations, 
and costs in patients undergoing cervical spinal deformity surgery.  
Methods  
Data Source  
This study obtained a sample of the MarketScan Commercial Claims and Encounters 
database (Truven Health Analytics, Ann Arbor, MI) from 1/1/2007 to 12/31/2016. This 
database is a collection of commercial inpatient, outpatient, and pharmaceutical claims of 
more than 75 million employees, retirees, and dependents representing a substantial portion 
18 years of age, with a history of tumor or trauma, or who underwent single-level fusions 
were excluded.  
Variables and Outcomes 
Patients were stratified into two cohorts based on the presence (BMP group) or absence of a 
BMP procedure code on the index deformity surgery date (no BMP group; control), and these 
cohorts were mutually exclusive. Individual demographic information and comorbidity status 
including history of diabetes, congestive heart failure (CHF), arterial hypertension, cardiac 
arrhythmia, liver disease, osteoporosis, and tobacco and alcohol use of each patient were 
gathered. Surgical approach type (anterior, posterior, or combined) was also noted (Table 1).  
 
The primary outcome of this study was the rate of reoperation following index surgery. This 
was measured at 90-days, 6 months, 1 year, and 2 years following admission for ACD 
surgery. A revision surgery was defined by the presence of the aforementioned CPT codes for 
deformity surgery after the index stay for the ACD surgery. A secondary outcome measure 
was the presence of a postoperative complication (defined as a complication occurring within 
90-days of the index deformity surgery). These included pulmonary complications, acute-
posthemorrhagic anemia, sepsis, central nervous system, cardiac, renal, or wound 
complications, deep vein thrombosis (DVT), pulmonary embolism (PE), acute kidney injury 
(AKI) or dysphagia (Table 2, Table 3).  
Healthcare utilization data were also collected. Payments (stratified into physician, hospital & 
total payments of the index hospitalization, as well as 90-day, 6-month, 1 year, and 2 years 
total payments) and 90-day readmission rates were included (Table 3). An analysis of the 
BMP use over time in anteriorly corrected deformity patients was also conducted (Figure 1).  
To isolate the impact of BMP on outcomes, a multivariate regression analysis was conducted 
with all significantly different baseline covariates (approach type, tobacco use). Outcomes of 
this analysis, with respect to complications and reoperation rate (Table 4). Two sample t-tests 
or chi-squared tests were used as appropriate. P values were interpreted as significant if p < 
0.05. Information about the level of significance is provided in each table caption. Statistical 
analysis was conducted in R Studio version 1.0.153. 
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Ethical considerations 
All data from these databases are de-identified, and thus this study is exempt from IRB 
approval in accordance with the Health Insurance Portability and Accountability Act of 1996. 
 
Results 
Patient Cohort  
A total of 13,549 patients underwent primary ACD surgery, of which 1155 (8.5%) had 
intraoperative BMP use. Patients who received an BMP were similarly aged (BMP: 52.1 
years, non-BMP: 51.5 years, p = 0.0710) and in both cohorts, approximately two-thirds of 
patients were female. Baseline rates of CHF, hypertension, diabetes, and osteoporosis were 
similar between cohorts. Tobacco use was higher in the BMP cohort (33.4% vs 29.0%, p < 
0.05). Anterior surgical approach was preferred in both cohorts, however, rates of posterior 
and combined surgery differed (p < 0.05) (Table 1).  
 
Complications 
The overall 90-day complication rate significantly varied between cohorts (P < 0.05). The 
complication rate was 27.6% in the non-BMP cohort and 31.1% in the BMP cohort.  The 
specific adverse events driving this effect were deficiency and posthemorrhagic anemia, 
occurring 1.3x and 1.23x more frequently after BMP use (p < 0.05). Rates of dysphagia, 
DVT, PE, and wound complications were similar between the two cohorts. (Table 2).   
 
Quality and health care utilization outcomes  
Patients in whose ACD procedures BMP was used had longer lengths of stay (4.0 days vs 3.7 
days, p < 0.05). The BMP cohort had significantly lower rates of revision surgeries at 90 days 
(14.5% vs 28.3%, p < 0.05), 6 months (14.9% vs 28.6%, p < 0.05), 1 year (15.7% vs 29.2%, 
p < 0.05), and 2 years (16.5% vs 29.9%, p < 0.05) following the index surgery. Costs of index 
hospitalization were significantly higher in the BMP cohort ($91,488 vs $80,211, p < 0.05). 
Hospital payments were individually higher in the BMP cohort (p < 0.05); however, 
physician payments were similar between BMP and non-BMP patients. Including payments 
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after discharge, BMP use in patients was associated with higher payments throughout the 2-
year follow-up period ($107,975 vs $97,620, p < 0.05) (Table 3). 
 
After controlling for baseline covariates (approach type, tobacco use) in multivariate 
regression, BMP use independently increased the odds for developing a postoperative 
complication (OR 1.22, 95% CI 1.1 – 1.4). BMP use also reduced the odds for a reoperation 
at all time points throughout the 2 years of follow-up (OR 0.49, 95% CI 0.4 – 0.6).  
 
The use of BMP during anterior cervical deformity correction decreased over the study 
period. In 2007, 13.5% of patients who underwent ACD surgery received BMP, whereas by 
2015, the number was 8.5%. This measures to a -37.0% decrease in BMP use over the study 
period in anterior cervical deformity surgery with a particularly prominent drop in the year of 




In 2002, BMP was approved for use in the United States by the FDA for ALIF 
procedures, as an alternative to iliac crest-bone grafts (ICBG).8 Since then, studies have 
demonstrated that patients treated with BMP intraoperatively experience shorter operative 
duration, lower blood loss, shorter length of stay, lower reoperation rates, and faster returns to 
work than those treated with ICBG.14,16,18 Given the complexity of adult spinal deformity 
cases, achieving solid arthrodesis can be quite challenging. As a result, off-label use of BMP 
to improve outcomes for spinal deformity cases has been of particular interest to spine 
surgeons. 
 This study utilized a large national administrative dataset to determine the impact of 
intraoperative BMP on postoperative complications and revision rates in patients undergoing 
anterior cervical deformity surgery. Though the groups of patients receiving intraoperative 
BMP and not receiving BMP were well matched, it is important to note that there was a 
higher rate of tobacco use among those patients receiving BMP treatment, a finding that may 
be attributed to the idea that surgeons tend to administer adjunct BMP to patients at risk for 
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
non-union. Despite this imbalance, we found that the revision rate was consistently higher 
among patients who did not receive intraoperative BMP. However, certain postoperative 
complications were significantly more common among patients who received adjunct BMP. 
Postoperative Complications 
 Though the initial industry-sponsored clinical trials evaluating the use of BMP in 
various common spine surgery procedures demonstrated nearly no side effects, several 
independent studies thereafter reported adverse effects of BMP use.20,26,27 In a study of 
328,468 spinal fusion patients, BMP use was independently associated with increased the 
odds of any postoperative complication (OR 1.43, 95% CI 1.1 – 1.7).28  Another study 
described higher rates of heterotopic ossification, infection, dysphagia, hematoma formation, 
and neurological deficits to be associated with BMP use in non-FDA approved spinal 
procedures.29 However, these findings may vary by procedure type and surgical approach, as 
one study found an increased incidence of complications with BMP use in anterior cervical 
fusion, whereas there was no such increase for thoracolumbar or posterior cervical fusions.30 
The fear of developing a postoperative complication following cervical deformity may be the 
driver of decreasing BMP use over time in anteriorly corrected patients described in this 
study. Our study also found an increased frequency of deficiency and posthemorrhagic 
anemia among patients who received BMP during surgery to correct cervical spinal 
deformity, though other complications previously reported in other procedures that utilized 
intraoperative BMP (e.g. dysphagia, deep vein thrombosis, wound infection) were not 
significantly more frequent. (Table 2) Further, these results are particularly interesting since 
surgeon use of BMP would be more common in more complex deformity cases, thus leading 
to a difference in patient selection in the groups.  
Revision Surgery 
 Additionally, our study assessed the effect of use of BMP on the reoperation rate after 
cervical deformity surgery. Many previous clinical trials have demonstrated that BMP 
improves the likelihood of solid fusion, which could potentially decrease the need for 
revision surgery.9-12 However, the literature regarding this topic is inconclusive, with some 
studies finding decreased reoperation rates, and others identifying no such difference.25,31 We 
discovered a significantly reduced revision surgery rate among patients treated with 
intraoperative BMP at 90 days postoperatively, and this effect persisted to 2 years 
postoperatively. Given the complexity of cervical spinal deformity cases, the risk for 
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hardware failure or non-union is quite high. Thus, the ability of BMP to reduce revision by 
increasing chances of arthrodesis in such cases is significant. However, previous studies have 
demonstrated that the impact of BMP on arthrodesis is not achieved until at least 6 months 
postoperatively.8,32,33 As such, the benefit to 90-day revision rates is likely due to other 
factors. For example, Jaeger and colleagues found that BMP had lower rates of 
instrumentation failure compared to autologous iliac crest bone graft  for isolated L5-S1 
ALIF.34 Considering all failures were identified by the 3 month follow-up visit in this study, 
it is possible that the decreased revision rate at early timepoint discovered in our study is due 
to decreased rate of hardware failure, whereas late benefits can be attributed to higher rates of 
arthrodesis. We hypothesized that the reduced revision rate would lower healthcare 
utilization, which has traditionally reached costs upward of $100,000 postoperatively.35,36 
However, our study found that total payments remained higher among patients who received 
intraoperative BMP up to 2 years after the index surgery (Table 3). Spine surgeons should use 
their judgement in administering BMP to cervical deformity patients, weighing increased 
likelihood of superior fixation against the likely development of postoperative complications 
and increased financial burden. 
Limitations 
The limitations of MarketScan analyses have been previously reported by this group. 
37-39 Due to the nature of the data available, potential questions and analyses are constrained 
by the specificity of the ICD-9 codes. For example, this study was not able to stratify by use 
of low vs high dose BMP. Furthermore, although only multilevel procedures were included in 
this study, we were unable to control for length of fusion, operative time, and blood loss -- 
factors which can impact postoperative complication rates. BMP may be used in situations 
where non-union is a concern or the surgery is more complex, and these operative 
characteristics were unavailable to us. However, there were significant efforts made to ensure 
validity of the findings. First, a relative homogenous cohort was assembled using cervical 
spine deformity surgery CPT codes. Nevertheless, we believe this study provides useful 
insight into the efficacy and safety of BMP in the surgical management of cervical spinal 
deformity.  
Conclusion  
Although the use of intraoperative BMP has demonstrated benefits in fusion integrity in ACD 
surgery, concern should remain with its association with increased rates of postoperative 
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complications. This study identified an increased rate of postoperative complications in 
patients who received BMP; however, this may be confounded by increased complexity of 
surgery. Spine surgeons should weigh these benefits and drawbacks in identify optimal 
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Figure 1. BMP Use in Anterior Deformity Correction Over Time. The percentage of anterior 
deformity cases from 2007-2015 that involved intraoperative BMP use (y-axis) was plotted 
by year (x-axis). 
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Table 1. Demographic and Clinical Factors 
 
Table 2. 90 Day Overall Complications 
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Table 3. Quality Outcomes 
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